Clinical Trials Browser

OTHER × Metastatic Pancreatic Ductal Adenocarcinoma × 90 days × Clear all

NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1/2 Recruiting

Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma